Second Chinese drugmaker seeks approval for Ozempic generic

By Andrew Silver SHANGHAI (Reuters) – A second Chinese drugmaker has applied for approval to sell a generic version of Novo Nordisk’s blockbuster diabetes drug Ozempic in China. Livzon Pharmaceutical Group said this week its subsidiary was seeking approval to…